Figure 2.
![SYK inhibition significantly reduces VITT plasma–induced procoagulant PLT response in WB. WB from healthy individuals was pretreated with SYK inhibitors R406 (5 μM), PRT-060318 (1 μM), entospletinib (5 μM), and lanraplenib (5 μM), or vehicle control (dimethyl sulfoxide [DMSO]) for 15 minutes before exposure to PLT agonist SFLLRN (5 μM) and HC or VITT plasma. Procoagulant PLTs were enumerated by FC. One-way analysis of variance with the Dunnett's multiple comparison test was performed. The number of patients tested is reported in each graph. ∗∗∗P < .001;∗∗∗∗P < .0001. N, number of patients tested.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/8/10.1182_bloodadvances.2024014167/1/blooda_adv-2024-014167-gr2.jpeg?Expires=1748327568&Signature=v6oDeYhpMjheHUGagoxx~QmGK7tZYcpAMAt3ce7ylJe830iA~iy7x9iqEJDvoletZuQp356fybO4hVHpf0sCoRHkLBdydFU6Seaf12pxYFYWm5eBIXghFETkQlItGo1sVoO7XMW1z70OXXC45j64qo3cPp52nyYROkGARHB8q4NwKdhrxmWdi6PY4ISaOnjyMNDorVBp5UOYG1WE6TiHpWpgIKpi4Ln3cCfElRmDk~JtPHYiUM022pxufVJ8cIVBzVY0aFuv9i~x5BvxRGyvfbRHNdKxodOxBbkwZ8BCkHLfbZl2piby1kGLF1lE9-orvu4xvcXhMV1Os7rOHG49bQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
SYK inhibition significantly reduces VITT plasma–induced procoagulant PLT response in WB. WB from healthy individuals was pretreated with SYK inhibitors R406 (5 μM), PRT-060318 (1 μM), entospletinib (5 μM), and lanraplenib (5 μM), or vehicle control (dimethyl sulfoxide [DMSO]) for 15 minutes before exposure to PLT agonist SFLLRN (5 μM) and HC or VITT plasma. Procoagulant PLTs were enumerated by FC. One-way analysis of variance with the Dunnett's multiple comparison test was performed. The number of patients tested is reported in each graph. ∗∗∗P < .001;∗∗∗∗P < .0001. N, number of patients tested.
